Vor Biopharma Net Income vs. Current Ratio
| VOR Stock | USD 0.88 0.07 7.36% |
Net Loss | First Reported 2019-12-31 | Previous Quarter -27.8 M | Current Value -27.6 M | Quarterly Volatility 8.3 M |
For Vor Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vor Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vor Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vor Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vor Biopharma over time as well as its relative position and ranking within its peers.
Vor |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vor Biopharma. If investors know Vor will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vor Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vor Biopharma is measured differently than its book value, which is the value of Vor that is recorded on the company's balance sheet. Investors also form their own opinion of Vor Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Vor Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vor Biopharma's market value can be influenced by many factors that don't directly affect Vor Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vor Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vor Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vor Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Vor Biopharma Current Ratio vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vor Biopharma's current stock value. Our valuation model uses many indicators to compare Vor Biopharma value to that of its competitors to determine the firm's financial worth. Vor Biopharma is rated below average in net income category among its peers. It is rated below average in current ratio category among its peers . Vor Biopharma reported last year Net Loss of (106.08 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Vor Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Vor Current Ratio vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Vor Biopharma |
| = | (117.86 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Vor Biopharma |
| = | 12.95 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Vor Current Ratio Comparison
Vor Biopharma is currently under evaluation in current ratio category among its peers.
Vor Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vor Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vor Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Vor Biopharma's change in net profit over the period of time. It can combine multiple indicators of Vor Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -69.3 K | -72.8 K | |
| Net Interest Income | 8.2 M | 8.6 M | |
| Interest Income | 8.2 M | 8.6 M | |
| Operating Income | -113.4 M | -107.8 M | |
| Net Loss | -104 M | -98.8 M | |
| Income Before Tax | -106.1 M | -100.8 M | |
| Total Other Income Expense Net | 9.4 M | 9.9 M | |
| Net Loss | -82.9 M | -78.7 M | |
| Net Loss | -106.1 M | -100.8 M | |
| Income Tax Expense | -1.2 M | -1.1 M | |
| Non Operating Income Net Other | 1.5 M | 793.6 K | |
| Change To Netincome | 12.3 M | 12.9 M | |
| Net Loss | (2.02) | (2.12) | |
| Income Quality | 0.77 | 0.69 | |
| Net Income Per E B T | 1.13 | 1.11 |
Vor Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vor Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vor Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vor Biopharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Vor Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Use Investing Themes to Complement your Vor Biopharma position
In addition to having Vor Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Staples ETFs Thematic Idea Now
Consumer Staples ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Staples ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Staples ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.